EA201490320A1 - Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a - Google Patents
Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5aInfo
- Publication number
- EA201490320A1 EA201490320A1 EA201490320A EA201490320A EA201490320A1 EA 201490320 A1 EA201490320 A1 EA 201490320A1 EA 201490320 A EA201490320 A EA 201490320A EA 201490320 A EA201490320 A EA 201490320A EA 201490320 A1 EA201490320 A1 EA 201490320A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- tetrahydropyridopyridine
- tetrahydropyridopyrimidine
- model
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Настоящее изобретение относится к соединению формулы Iк способу получения соединений по изобретению и их терапевтическому применению. Настоящее изобретение, кроме того, относится к комбинации фармакологически активного средства и фармацевтической композиции.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161510643P | 2011-07-22 | 2011-07-22 | |
US201161539732P | 2011-09-27 | 2011-09-27 | |
PCT/US2012/047617 WO2013016197A1 (en) | 2011-07-22 | 2012-07-20 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201490320A1 true EA201490320A1 (ru) | 2014-06-30 |
Family
ID=46604083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201490320A EA201490320A1 (ru) | 2011-07-22 | 2012-07-20 | Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a |
Country Status (25)
Country | Link |
---|---|
US (2) | US8846656B2 (ru) |
EP (1) | EP2734521B1 (ru) |
JP (1) | JP6040237B2 (ru) |
KR (1) | KR20140096020A (ru) |
CN (1) | CN103814027B (ru) |
AP (1) | AP2014007398A0 (ru) |
AR (1) | AR087288A1 (ru) |
AU (1) | AU2012287183B2 (ru) |
BR (1) | BR112014001468A2 (ru) |
CA (1) | CA2842528A1 (ru) |
CL (1) | CL2014000171A1 (ru) |
CO (1) | CO6862157A2 (ru) |
CR (1) | CR20140032A (ru) |
EA (1) | EA201490320A1 (ru) |
ES (1) | ES2637167T3 (ru) |
IL (1) | IL230501A0 (ru) |
MA (1) | MA35275B1 (ru) |
MX (1) | MX336497B (ru) |
PE (1) | PE20141281A1 (ru) |
PL (1) | PL2734521T3 (ru) |
PT (1) | PT2734521T (ru) |
TN (1) | TN2014000030A1 (ru) |
TW (1) | TW201311688A (ru) |
UY (1) | UY34209A (ru) |
WO (1) | WO2013016197A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2794327C2 (ru) * | 2018-04-02 | 2023-04-17 | Кемосентрикс, Инк. | ПРОЛЕКАРСТВА СОПРЯЖЕННО-БИЦИКЛИЧЕСКИХ АНТАГОНИСТОВ C5aR |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012035078A1 (en) * | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
BR112014027359A2 (pt) * | 2012-05-04 | 2017-07-18 | Novartis Ag | moduladores da série de reação complementar e usos dos mesmos |
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
JP6387391B2 (ja) * | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 眼科疾患の処置に有用な補体因子B阻害剤としての2−(1H−インドール−4−イルメチル)−3H−イミダゾ[4,5−b]ピリジン−6−カルボニトリル誘導体 |
PE20152033A1 (es) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | Heterociclos bicicliclos como inhibidores de fgfr |
WO2015061690A1 (en) | 2013-10-24 | 2015-04-30 | Trustees Of Boston University | Infusion system for preventing mischanneling of multiple medicaments |
JP2016535042A (ja) | 2013-10-30 | 2016-11-10 | ノバルティス アーゲー | 2−ベンジル−ベンゾイミダゾール補体因子b阻害剤およびその使用 |
TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016107832A1 (en) | 2014-12-30 | 2016-07-07 | F. Hoffmann-La Roche Ag | Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MA48800A (fr) | 2017-05-31 | 2020-04-08 | Chemocentryx Inc | Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a |
KR102638253B1 (ko) | 2017-05-31 | 2024-02-16 | 케모센트릭스, 인크. | C5a 억제제로서의 6-5 융합 고리 |
LT3728254T (lt) | 2017-12-21 | 2023-05-10 | Boehringer Ingelheim International Gmbh | Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai |
BR112020012374A2 (pt) | 2017-12-22 | 2020-11-24 | Chemocentryx, Inc. | compostos de anel 5,5-fundido substituído por diarila como inibidores de c5ar |
CN111788185A (zh) | 2017-12-22 | 2020-10-16 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的二芳基取代的6,5稠合环化合物 |
ES2933820T3 (es) * | 2018-01-10 | 2023-02-14 | Idorsia Pharmaceuticals Ltd | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidina-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de la vasculitis y las enfermedades inflamatorias |
SG11202009588PA (en) * | 2018-04-02 | 2020-10-29 | Chemocentryx Inc | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
CN112867716A (zh) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
JP2023514328A (ja) * | 2020-02-17 | 2023-04-05 | アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ | Gcn2モジュレーター化合物 |
EP4214204A1 (en) | 2020-09-18 | 2023-07-26 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
TW202233576A (zh) * | 2020-10-30 | 2022-09-01 | 日商第一三共股份有限公司 | 3-甲基-鹵-吲哚衍生物之製造方法 |
EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4727149A (en) | 1982-03-11 | 1988-02-23 | John Wyeth & Brother Limited | Preparation of nitriles of fused ring pyridine derivatives |
US5853740A (en) | 1996-08-07 | 1998-12-29 | Abbott Laboratories | Delivery system for pharmaceutical agents encapsulated with oils |
AU2001292670A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2003253130A1 (en) | 2002-08-19 | 2004-03-03 | Glenmark Pharmaceuticals Limited | Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
JP2006521398A (ja) | 2003-03-28 | 2006-09-21 | サイオス・インコーポレーテツド | TGFβの二−環式ピリミジン阻害剤 |
CN1777584A (zh) | 2003-04-18 | 2006-05-24 | 伊莱利利公司 | 作为5-ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物 |
TW200521119A (en) * | 2003-08-05 | 2005-07-01 | Vertex Pharma | Compositions useful as inhibitors of voltage-gated ion channels |
GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
TW200608976A (en) | 2004-05-08 | 2006-03-16 | Neurogen Corp | 4,5-disubstituted-2-aryl pyrimidines |
US7429666B2 (en) | 2004-06-10 | 2008-09-30 | Merck Frosst Canada Ltd. | Pyridine analogs as C5a antagonists |
TW200626157A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HCV inhibiting bi-cyclic pyrimidines |
CN102627640A (zh) | 2005-08-12 | 2012-08-08 | 默沙东公司 | 可用作p38激酶抑制剂的杂二环化合物 |
AU2007242883B2 (en) | 2006-04-20 | 2012-09-27 | F. Hoffmann-La Roche Ag | Diazepan derivatives modulators of chemokine receptors |
US20090124610A1 (en) | 2006-04-25 | 2009-05-14 | Gordon Saxty | Pharmaceutical compounds |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
US20090048295A1 (en) | 2007-08-13 | 2009-02-19 | Joseph Kent Barbay | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
BRPI0911688A2 (pt) | 2008-07-31 | 2015-07-28 | Genentech Inc | "compostos de pirimidina, composições e métodos de uso" |
WO2010028174A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Novel biccyclic compounds as gata modulators |
AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
US20120244192A1 (en) | 2009-04-27 | 2012-09-27 | Cook Gary P | Sustained release formulations of peptidomimetic drugs and uses thereof |
US8492392B2 (en) | 2009-05-27 | 2013-07-23 | Merck Sharp & Dohme Corp. | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors |
WO2011022213A1 (en) | 2009-08-17 | 2011-02-24 | Merck Sharp & Dohme Corp. | Amino tetrahydro-pyridopyrimidine pde10 inhibitors |
JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
CA2862895A1 (en) | 2011-09-30 | 2013-04-04 | Kineta, Inc. | Anti-viral compounds |
WO2013082535A2 (en) | 2011-12-02 | 2013-06-06 | Board Of Regents Of The University Of Nebraska | Controlled-release peptide compositions and uses thereof |
-
2012
- 2012-07-19 US US13/553,120 patent/US8846656B2/en not_active Expired - Fee Related
- 2012-07-20 UY UY0001034209A patent/UY34209A/es not_active Application Discontinuation
- 2012-07-20 MX MX2014000898A patent/MX336497B/es unknown
- 2012-07-20 EP EP12743023.9A patent/EP2734521B1/en active Active
- 2012-07-20 KR KR1020147004232A patent/KR20140096020A/ko not_active Application Discontinuation
- 2012-07-20 WO PCT/US2012/047617 patent/WO2013016197A1/en active Application Filing
- 2012-07-20 BR BR112014001468A patent/BR112014001468A2/pt not_active Application Discontinuation
- 2012-07-20 CA CA2842528A patent/CA2842528A1/en not_active Abandoned
- 2012-07-20 AU AU2012287183A patent/AU2012287183B2/en not_active Ceased
- 2012-07-20 EA EA201490320A patent/EA201490320A1/ru unknown
- 2012-07-20 AP AP2014007398A patent/AP2014007398A0/xx unknown
- 2012-07-20 PT PT127430239T patent/PT2734521T/pt unknown
- 2012-07-20 PL PL12743023T patent/PL2734521T3/pl unknown
- 2012-07-20 JP JP2014521829A patent/JP6040237B2/ja not_active Expired - Fee Related
- 2012-07-20 PE PE2014000114A patent/PE20141281A1/es not_active Application Discontinuation
- 2012-07-20 ES ES12743023T patent/ES2637167T3/es active Active
- 2012-07-20 CN CN201280045758.6A patent/CN103814027B/zh not_active Expired - Fee Related
- 2012-07-20 TW TW101126407A patent/TW201311688A/zh unknown
- 2012-07-23 AR ARP120102669A patent/AR087288A1/es unknown
-
2014
- 2014-01-16 IL IL230501A patent/IL230501A0/en unknown
- 2014-01-20 MA MA36696A patent/MA35275B1/fr unknown
- 2014-01-20 TN TNP2014000030A patent/TN2014000030A1/en unknown
- 2014-01-22 CR CR20140032A patent/CR20140032A/es unknown
- 2014-01-22 CL CL2014000171A patent/CL2014000171A1/es unknown
- 2014-01-24 CO CO14014580A patent/CO6862157A2/es active IP Right Grant
- 2014-08-08 US US14/455,848 patent/US9505755B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2794327C2 (ru) * | 2018-04-02 | 2023-04-17 | Кемосентрикс, Инк. | ПРОЛЕКАРСТВА СОПРЯЖЕННО-БИЦИКЛИЧЕСКИХ АНТАГОНИСТОВ C5aR |
Also Published As
Publication number | Publication date |
---|---|
AR087288A1 (es) | 2014-03-12 |
TW201311688A (zh) | 2013-03-16 |
MA35275B1 (fr) | 2014-07-03 |
AU2012287183B2 (en) | 2014-11-20 |
CR20140032A (es) | 2014-05-16 |
WO2013016197A1 (en) | 2013-01-31 |
CA2842528A1 (en) | 2013-01-31 |
IL230501A0 (en) | 2014-03-31 |
CL2014000171A1 (es) | 2014-10-03 |
CO6862157A2 (es) | 2014-02-10 |
EP2734521A1 (en) | 2014-05-28 |
BR112014001468A2 (pt) | 2017-01-10 |
JP2014521607A (ja) | 2014-08-28 |
CN103814027A (zh) | 2014-05-21 |
PE20141281A1 (es) | 2014-09-24 |
PT2734521T (pt) | 2017-08-11 |
AP2014007398A0 (en) | 2014-01-31 |
JP6040237B2 (ja) | 2016-12-07 |
PL2734521T3 (pl) | 2017-10-31 |
US9505755B2 (en) | 2016-11-29 |
CN103814027B (zh) | 2016-07-06 |
UY34209A (es) | 2013-02-28 |
MX336497B (es) | 2016-01-21 |
US20140349995A1 (en) | 2014-11-27 |
EP2734521B1 (en) | 2017-05-10 |
TN2014000030A1 (en) | 2015-07-01 |
ES2637167T3 (es) | 2017-10-11 |
US20130184253A1 (en) | 2013-07-18 |
KR20140096020A (ko) | 2014-08-04 |
AU2012287183A1 (en) | 2014-01-30 |
US8846656B2 (en) | 2014-09-30 |
MX2014000898A (es) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201490320A1 (ru) | Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a | |
EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
PH12016500777B1 (en) | Compositions and methods for modulating farnesoid x receptors | |
EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
EA201391000A1 (ru) | Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd) | |
EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
EA201390723A1 (ru) | Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep | |
EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
MX364400B (es) | Compuestos de tetraciclina. | |
EA201391524A1 (ru) | Производные гликозида и их применение | |
EA201391056A1 (ru) | Гетероарильные соединения в качестве лигандов 5-htрецептора | |
UY33348A (es) | Compuestos de furopiridina y usos de los mismos | |
EA201391124A1 (ru) | Новые бензодиоксолпиперазиновые соединения | |
EA201591177A1 (ru) | Трициклические соединения для ингибирования канала cftr | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
EA201692090A1 (ru) | Полициклические активаторы herg |